Singapore, April 29 -- Chongqing Claruvis Pharmaceutical, a subsidiary of MingMed Biotechnology, has announced that the China's National Medical Products Administration (NMPA) has approved its Retoxin(R) (recombinant botulinum toxin type A, project code YY001) for the temporary improvement of moderate-to-severe glabellar lines in adult patients.

Retoxin(R) is the world's first approved recombinant botulinum toxin type A, marking a significant technological shift from traditional botulinum toxin products derived from Clostridium botulinum extraction to a precision-engineered recombinant manufacturing process.

Developed using Claruvis Pharmaceutical's proprietary recombinant platform and manufacturing system, Retoxin(R...